Emerging data on new tau ligands raise hope of more signal, less noise, and help with a broad range of tauopathies. Read news culled from the AD/PD and HAI 2017 meetings.
By virtue of its heavy hydrogen, deutetrabenazine resists metabolism by liver enzymes, allowing clinicians to better titrate the drug.
People who developed epilepsy as children were more likely to have amyloid in their brains 50 years later, especially if they carried the ApoE4 allele.
Although shorter tau peptides formed fibrils in a dish, the R3 domain of tau seeded aggregation in cells.
Antibodies against tau lower APP expression and degrade Aβ plaques in transgenic mice.
Unlikely a disease marker, poly glycine-proline might track therapeutic efficacy in clinical trials.
The largest study yet on neurofilament light chain suggests plasma levels rise with disease and correlate with other signs of neurodegeneration.
Unbiased screen turns up genes expressed in immune cells, both inside and outside the CNS.
Scientists derive a genetic score that predicts the likely age at which a person will develop Alzheimer’s disease.
Daily doses of the antioxidants vitamin E and/or selenium did not reduce incidence of dementia in cognitively normal older men in a randomized, controlled trial.
The toxic Aβ accumulated at postsynapses of a mouse model one month before plaques developed.
A report claims that in the U.K. dementia research grew substantially since 2008, but more gains are needed to find treatments.
Trials enrolling people all at the same Braak stage would need fewer participants to show a drug effect, according to a new analysis.
Route to toxicity converges with RNA binding proteins in membrane-less organelles.
The proposed budget would strike a blow to biomedical research, and science in general.